Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | VCP | P55072 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | PNP | P00491 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | EDNRA | P25101 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | HBB | P68871 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL3033 | 1.00 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10899902 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481442 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2433042 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481436 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL1242615 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL25915 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11093368 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10901635 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11121521 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362436-A | anti-PD-L1 antibodies and uses thereof | 桂林三金药业股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230364247-A1 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS | THE JOHNS HOPKINS UNIVERSITY | 2023-11-16 | — | — | US | disclosed |
| EP-4212177-A1 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOPIC AND HETEROPIC XENOGENEIC HEART TRANSPLANTATIONS | Reichart, Bruno (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-11660349-B2 | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4154912-A1 | DONOR ORGANISM FOR XENOGENEIC ORGAN TRANSPLANTS | Reichart, Bruno (DE) | 2023-03-29 | — | — | EP | disclosed |
| US-20210177979-A1 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS | THE JOHNS HOPKINS UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| US-20210105999-A1 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS | REICHART, BRUNO (DE) | 2021-04-15 | — | — | US | disclosed |
| US-10933144-B2 | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3773570-A2 | COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOPIC AND HETEROPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS | Reichart, Bruno (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-2825207-B1 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS | UNIV JOHNS HOPKINS (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| CN-1344270-A | Functionalized heterocycles as chemokine receptor modulators | THOUSAND YEARS MEDICAMENTS INC (US) | 2002-04-10 | — | — | CN | disclosed |
| US-6316449-B1 | Chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5840890-A | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | SYNTEX (U.S.A.) INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0493770-B1 | Antiherpes compositions | BOEHRINGER INGELHEIM CA LTD (CA) | 1997-08-06 | — | — | EP | disclosed |
| US-5552384-A | Antiherpes compositions and method of use | BIO-MEGA BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-09-03 | — | — | US | disclosed |
| US-5380727-A | Antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative | BIO-MEGA, INC. (CA) | 1995-01-10 | — | — | US | disclosed |
| EP-0493767-A2 | Synergistic combination for treating herpes infections | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1992-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660349-B2 | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents | VEGFA, UACA, PDE6A | BLM 4151/4885MEN1 2861/4885KMT2A 3704/4885 |
| US-20230364247-A1 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS | VEGFA, UACA, PDE6A | BLM 4151/4885MEN1 2861/4885KMT2A 3704/4885 |
| US-10933144-B2 | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents | VEGFA, UACA, PDE6A | BLM 4151/4885MEN1 2861/4885KMT2A 3704/4885 |
| US-20210177979-A1 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS | VEGFA, UACA, PDE6A | BLM 4151/4885MEN1 2861/4885KMT2A 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.